The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Saul Hadassin is an analyst at UBS. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 03/25/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 01/25/2024 | RMD | Buy Now | ResMed | $221.09 | -18.59% | Saul Hadassin66% | $175 → $180 | Maintains | Neutral | Get Alert |
| 09/05/2023 | RMD | Buy Now | ResMed | $221.09 | -23.11% | Saul Hadassin66% | $265 → $170 | Downgrade | Buy → Neutral | Get Alert |
| 05/22/2023 | RMD | Buy Now | ResMed | $221.09 | 31.17% | Saul Hadassin66% | → $290 | Initiates | → Buy | Get Alert |
| 01/31/2020 | RMD | Buy Now | ResMed | $221.09 | -21.3% | Saul Hadassin66% | $150 → $174 | Downgrade | Buy → Neutral | Get Alert |
| 07/29/2019 | RMD | Buy Now | ResMed | $221.09 | -36.68% | Saul Hadassin66% | $122 → $140 | Upgrade | Neutral → Buy | Get Alert |
| 05/06/2019 | RMD | Buy Now | ResMed | $221.09 | — | Saul Hadassin66% | — | Upgrade | Neutral → Buy | Get Alert |
| 08/02/2017 | RMD | Buy Now | ResMed | $221.09 | — | Saul Hadassin66% | — | Downgrade | Outperform → Neutral | Get Alert |
| 01/22/2016 | RMD | Buy Now | ResMed | $221.09 | -96.06% | Saul Hadassin66% | $8.4 → $8.7 | Upgrade | Neutral → Outperform | Get Alert |
| 04/07/2015 | RMD | Buy Now | ResMed | $221.09 | — | Saul Hadassin66% | — | Upgrade | Neutral → Outperform | Get Alert |
| 10/25/2013 | RMD | Buy Now | ResMed | $221.09 | — | Saul Hadassin66% | — | Upgrade | Neutral → Buy | Get Alert |
| 07/30/2013 | RMD | Buy Now | ResMed | $221.09 | — | Saul Hadassin66% | — | Upgrade | Neutral → Buy | Get Alert |
| 08/06/2012 | RMD | Buy Now | ResMed | $221.09 | — | Saul Hadassin66% | — | Upgrade | Neutral → Outperform | Get Alert |
